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In antibody-dependent, lymphocyte-mediated cytotoxicity (ADCC),  ~ the interac- 
tion between IgG antibodies on the target cells and Fc IgG receptors (FcTR)  on the 
effector cells affords close contact  between  the cells resulting in  lysis of the targets. 
Present evidence suggests that the Fc-FcTR interaction triggers the cytolytic reaction. 
(1). It has been shown earlier that lymphoid effector cells with C3 receptors can bind 
C3-fragment-bearing  erythrocytes  as  assessed  by  rosette  formation.  However,  this 
interaction did not result in lysis of the target cells in absence of IgG antibody (2-4). 
In the presence of antibody to the target cells, target cell-bound C3 fragments strongly 
enhanced  ADCC  (1,  5).  It  was  concluded  that  target  cell-associated C3  amplifies 
ADCC by improving effeetor cell-target cell contact. 
Cell-bound C3  may exist  in several molecular forms,  designated C3b,  C3bi,  and 
C3d  (reviewed  in  [6]).  C3  is  deposited on  particles  as  C3b  which  subsequently  is 
cleaved by factor I to form C3bi without reduction of molecular weight. C3bi is then 
converted to C3d by enzymatic removal of the C3c fragment. The relative proportions 
of the  three  fragments  on  the  surface  of a  target  are  determined  by  exposure  to 
controlling enzymes. 
The  question  of the  role  of these  different  C3  fragments  in  regulating  cellular 
effector  functions  such  as  ADCC  or  phagocytosis  is  largely unresolved.  Although 
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1  Abbreviations  used  in this paper: ADCC, antibody-dependent, lymphocyte-mediated cytotoxicity; complete 
TCM,  Hepes  (10  mM)  -buffered  RPMI-1640  containing  0.4% HSA and  supplemented  with  100  U 
penicillin,  100 #g Fungizone, and 2 mM L-glutamine; Eb, E¢, Es, bovine, chicken, or sheep erythrocytes, 
respectively;  EbC3b,  EbC3bi, EbC3d, C3b-fragment-,  C3bi-fragment-,  and  C3d-fragment-bearing  Eb, 
respectively; FcTR, Fc IgG receptor; FIP, Ficoll-Isopaque; GBV  ++, veronal-buffered physiological saline, 
pH  7.4, containing 0.15 mM CaCI2; HSA, human serum albumin; NF, nephritic  factor;  PFC, plaque- 
forming cells; PMN, polymorphonuelear  leukocytes; TH, Hanks' balanced salt solution containing 15 mM 
Tris, pH 7.2; UV, ultraviolet. 
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previous studies suggested that target cell-bound C3b and C3d might enhance ADCC, 
no  conclusions  as to their relative importance could be drawn  (3).  Moreover, C3bi 
was not clearly defined at that time. This is the first description of a  role for C3bi in 
lymphocyte  function.  The  present  study  shows  that  cell-bound  C3bi  can  directly 
interact  with  certain  lymphocytes  and  that  in  the  case  of ADCC,  this  interaction 
greatly enhances lysis of target cells. The enhancing effect of C3bi is greater than that 
of C3d, and considerably greater than that of C3b. 
Materials  and  Methods 
Buffers.  Buffers used were as follows: GVB++: veronal-buffered physiological saline, pH 7.4, 
containing 0.15 mM CaC12, 0.5 mM MgCi2, and 0.1% gelatin; and TH: Hanks' balanced salt 
solution containing 15 mM Tris, pH 7.2. 
Purified Proteins.  The proteins C3  (7),  factor B  (8), C3b inactivator (9), and fllH (9) were 
prepared  as described previously. Partially purified nephritic  factor  (NF)  was  prepared as 
described previously (10).  1 ml of NF was absorbed three times for 20 min at 0°C with  109 
erythrocytes and one time with 109 erythrocytes bearing C3 fragments (EC3b). Bovine conglu- 
tinin was prepared by the method of Lachmann  (l 1). Trypsin (TPCK) was purchased from 
Worthington Biochemical Corp. (Freehold, N. J.). 
Erythrocytes.  Bovine  erythrocytes  (Eb) and  sheep  erythrocytes  (E~) were  purchased  from 
Colorado Serum  Co.,  Denver,  Colo. and  used within  2  wk.  Chicken erythrocytes (Ec) were 
prepared from heparinized blood of 10-20-wk-old white Leghorns as previously described. (12). 
Preparation of EC3b.  EC3b  were prepared by a  modification of the procedure published 
elsewhere (13).  6 ×  109 washed erythrocytes were mixed with 800 ~g C3 and  1.5 #g x25I-C3 in 
a total vol of 500 ~1 GVB  ÷+. Deposition of C3b from the fluid phase onto the cell surface was 
effected by addition of 24 gg trypsin and incubation for 2.5 min at 23 °. Cells were washed 3 
times  with  10  ml  GVB  ++  and  resuspended  in  500  ~1  GVB  ÷+.  Formation  of cell-bound, 
alternative C3 convertase was accomplished by addition of 500 #g factor B, 300 ng factor D, 30 
gg NF, and sufficient MgSO4 to give a  final concentration of 1.2 mM and incubation for  15 
min  at  37°C.  Cells were  washed  two  times  in  GVB  ++  and  suspended  in  0.5  ml  GVB  ++ 
containing 800 gg C3 and  1.5 ~g z25I-C3. C3 deposition by the cell-bound C3 convertase was 
effected by incubation for 2.5 h  at 37°C or 1 h  at 37°C and  16 h at 4°C. Cells were washed 
three times into the appropriate buffer and standardized to 109/ml. The number of C3b bound 
per cell was determined by assessing the radioactivity associated with a  50-~1 sample of cells. 
Erythrocytes bearing C3bi  fragments  (EC3bi)  were  produced by incubation  for 45  min  at 
37°C of EC3b with purified C3b inactivator (8.0 #g/ml) and flirt (40.0/Lg/ml). Erythrocytes 
bearing C3d  fragments  (EC3d)  were  produced  from  EC3bi  by  incubation  with  10  gg/ml 
trypsin. 
Testing of Cellular Intermediates.  The  functional state of C3  fragments on erythrocytes was 
ascertained using a series of assays. C3/C5 convertase formation was determined by the ability 
of erythrocytes to be lysed by incubation with factors B and D and guinea pig C3-9 as described 
(14).  Immune adherence reactivity was determined in microtiter plates using human erythro- 
cytes as published previously (15). Conglutinin-dependent hemagglutination was performed in 
microtiter plates containing 2.5 ×  106 erythrocytes, serial-dilutions of bovine conglutinin, and 
GVB  ++ to a total vol of 75 ~1. 
Antisera.  Antisera to Eb or Ec were prepared in rabbits by six intravenous injections during 
a period of 10 d. IgG fractions of the antisera were prepared by gel-exclusion chromatography 
on Sephadex G-200 (Pharmacia Fine Chemicals, Uppsala, Sweden) (16). Anti-Eb reacted with 
Eb but not with Ec as determined by hemagglutination (titer: 21 gg/ml) and ADCC-induction, 
whereas the reverse was true for anti-Ec. Both antibody preparations reacted with Es. 
Lymphocytes.  Human peripheral blood lymphocytes were isolated and purified as previously 
described (12).  In brief, after defibrination of the blood with glass beads, a leukocyte-enriched 
fraction was prepared by gelatin sedimentation. Phagocytes and adhering cells were removed 
by treatment with earbonyl iron powder, followed by centrifugation through Ficoll-Isopaque 
(FIP; Pharmaeia Fine Chemicals). The lymphoeytes, collected at the interface, were kept at 
4°C overnight in Hepes (10 mM)-buffered RPMI-1640  (Grand Island Biological Co., Grand 
Island, N. Y.)  containing 0.4%  human serum albumin (HSA; Cutler Laboratories, Berkeley, 1594  ENHANCEMENT  OF ANTIBODY-MEDIATED CELLULAR CYTOTOXICITY 
Calif.) and supplemented with 100 U penicillin, 100 #g/ml Fungizone (Grand Island Biological 
Co.), and 2 mM L-glutamine (complete TCM). They were used the next day after centrifugation 
and suspension in fresh complete TCM. HSA was used as protein supplement throughout these 
experiments. 
FcyR Modulation of Lymphocytes.  1.6 ×  l0  s lymphocytes and 4 ×  106 Eb or Ec were mixed in 
a 50-ml Falcon tube (Falcon Labware, Div. of Beeton, Dickinson & Co., Oxnard, Calif.) in a 
total vol of 12 ml complete TCM in the presence of anti-Eb or~l anti-Ec (IgG fractions). The 
antibody concentrations were chosen to give 80-90% lysis of  Cr-labeled erythrocytes when 
mixed with aliquots of the tymphocytes at the same ratios under ADCC conditions. After 20 h 
(or, in one experiment, 40 h)  of incubation at 37°C, the cells were washed once in TH, and 
were then suspended in complete TCM at a concentration of 4 ×  108 lymphocytes/ml. Control 
lymphocytes were  mixed  with  erythrocytes  and  processed  similarly but  in the  absence of 
antibody. When lymphocytes, modulated by exposure to antibody-coated erythrocytes, were 
mixed with fresh  51Cr-labeled  target erythrocytes (Es) under ADCC conditions but without 
addition of fresh antibody, no lysis ensued (of. Table II), indicating that no antibody had been 
transferred with the lymphocytes in these experiments (17). 
Fractionation of Lymphocytes by Adsorption to Monolayers of C3-fragment-bearing Eb.  Tissue culture 
dishes (Falcon 3002;  60 ×  15 mm) were treated for  1 h with 2 ml TH containing 50 pg/ml 
poly-L-lysine (70,000 mol wt; Sigma Chemical Co.,  St.  Louis, Mo.). After washing, 2 ml TH 
containing 4  X  108  Eb  bearing either C3b,  C3bi, or  C3d,  were  added  to  the  dishes.  The 
erythrocytes were allowed to settle at room temperature. After 40 min of incubation, nonad- 
sorbed Eb were washed off with TH. 8  ×  106 lymphocytes in 3 ml of complete TCM were 
added to the monolayers and incubated for 15 min at 37°C. The dishes were then centrifuged 
for 5 min at  100 g. After 15 rain at 4°C, the nonadhering lymphocytes were carefully decanted 
with a  Pasteur pipette and pooled with three additional washes  (2 ml of TH wash per dish). 
The lymphocytes were  then washed  in TH,  and finally suspended in complete TCM  at  a 
concentration of 4  ×  105 living cells/ml. Recovery of lymphocytes from C3-free Eb control 
monolayers was ~ 100%. 
Fractionation of Lymphocytes by Rosetting with C3-fragment-bearing Eo.  1.6 ×  105 lymphocytes, 
suspended in 1 ml complete TCM, were mixed in conical 15-ml tubes (Falcon 2098) with l ml 
TH containing 4  ×  10  a Eb bearing either C3b, C3bi, or C3d  (EbC3b,  EbC3bi, and EbC3d). 
After 5 min of incubation at 37°C, the tubes were centrifuged for 5 rain at  100 g. After 1 h 
additional incubation at  4°C,  the  cell  mixtures were  gently suspended, diluted with  3  ml 
complete TCM, and layered over 1.5 ml FIP. After centrifugation for 20 min at  1,200 g, the 
nonrosetting lymphocytes were  collected at  the  interface washed  in TH  and suspended in 
complete TCM at a concentration of 3 ×  106 living cells/ml. 
ADCC.  ADCC of erythrocytes (Eb, E~, or Ec, respectively)  was assayed as described (12). 4 
×  l0  s lymphocytes were mixed with 105 ~lCr-labeled erythrocytes, either untreated or bearing 
C3 fragments, in the presence or absence of anti-erythrocyte antibodies (IgG fractions). The 
total vol of the incubation mixture was 0.3 ml. All mixtures were prepared in duplicate and 
incubated for  18 h at 37°C. After centrifugation for  10 min at 800 g, the release  of SICr was 
determined. 
Rosette Formation with C3-Fragment-bearing  Eb.  0.1 ml lymphocytes in complete TCM (4 ×  106 
lymphocytes/ml) were thoroughly mixed with 0.1 ml Eb, EbC3b, EbC3bi, or EbC3d  (109/ml). 
The mixtures were incubated for 15 rain at 37°C, centrifuged for 5 min at  100 g and held at 
4°C overnight. Raji and Daudi cells  were  washed  three  times with TH  and suspended in 
complete TCM at a concentration of 2 X  105 cells/ml. For rosetting, 0.1  ml of the cells was 
mixed with 0.1 ml C3-fragment-bearing  Eb as described above. Drops of the cell mixtures were 
transferred to slides  and covered with cover slips,  coated with a  0.001% ethanol solution of 
acridine orange for nuclear staining of the lymphocytes (18). The percentage of rosetting cells 
was  determined by counting 600-800 cells  (two  slides  per sample)  in the  ultraviolet (UV) 
microscope under visible and UV light. 
Results 
Identification of Target Cell-bound C3 Fragments.  Table I defines the characteristics of 
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TABLE  I 
Identification of C3 Fragments on Cellular Intermediate Complexes 
Property 
Intermediate complex 
EC3b  EC3bi  EC3d 
C3-associated 12zI*  100  100  10 
C3/C5 convertase:]:  100  0  0 
Immune adherence4~  100  0  0 
Conglutination§  0  100  0 
* Data are represented as percentages of C3b radioactivity. 
~: Data are represented as percentages of lysis. 
§ Data are represented as percentages of activity. 
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FIG.  1.  Enhancement  of ADCC by target cell-bound  C3 fragments. 51Cr-labeled Eb lacking C3 
fragments (0) or bearing 45,000 C3b (A), C3bi (O), or C3d (A) molecules per cell were incubated 
with lymphocytes and anti-Eb antibody (13 mg IgG/ml stock solution) for 18 h. at an E:T ratio of 
4:1 as described in Materials and Methods. Spontaneous 51Cr release was 8% for Eb and EbC3b, and 
13% for EbC3bi and EbC3d. The release in the antibody-free lymphocyte controls was the same as 
the spontaneus release (4- 1%). 
positive immune  adherence reactivity with  human  erythrocytes and of forming the 
alternative pathway  C3/C5  convertase with  factors  B  and  D  and  magnesium  ions. 
Cells bearing C3bi were lacking the above functions, but exhibited the unique ability 
to  be  agglutinated by  purified bovine conglutinin  in  the  presence  of calcium  ions. 
Cells bearing C3d lacked all the above functions, but retained 10% of the radioactivity 
previously  associated  with  C3b.  A  minimum  of  100  C3b  molecules  or  500  C3bi 
molecules could be detected per cell by the functional tests. 
Enhancement of ADCC by  Target Cell-bound C3bi and C3d.  To establish the effect of 
target cell-bound C3 fragments on cell-mediated lysis, EbC3b, EbC3bi, or EbC3d were 
incubated with highly purified lymphocytes either in the absence or in the presence 
of rabbit anti-Eb (IgG fraction). Fig.  1 shows specific 51Cr release from the target cells 
after  18  h  of incubation.  The  spontaneous  51Cr  release  from  C3-fragment-bearing 
erythrocytes was comparable to that observed with erythrocytes lacking C3 fragments. 
Target cells with C3b, C3bi, or C3d were not lysed by the lymphocytes in absence of 
antibody. However, all three fragments enhanced ADCC. Enhancement was between 
5- and  15-fold at suboptimal antibody concentration.  The  number of C3  molecules 
per target cell varied from  15,000  to  100,000,  and very similar results were obtained 
in  replicate experiments.  The  enhancing  effects of the C3  fragments  ranked  in  the 1596  ENHANCEMENT  OF ANTIBODY-MEDIATED  CELLULAR CYTOTOXICITY 
order  of C3bi  >  C3d  >>  C3b.  The  enhancing  effect  of C3b  was  very  weak.  The 
magnitude  of  enhancement  by  the  fragments  varied  with  different  lymphocyte 
preparations. 
To study the effect of enhancement  by C3  fragments on modulated lymphocytes, 
lymphocytes were incubated at 37°C with antibody-coated Eb or Ec before they were 
used as effector cells. This treatment is known to remove FcyR from the lymphocyte 
surface (19, 20)  and, hence, to strongly reduce their ADCC potential. However, their 
natural cytotoxicity is unchanged or even increased as determined by lysis of nucleated 
target  cells in  the  absence of antibody  (21,  22).  Table II shows  the results of three 
experiments in which modulated lymphocytes were used with Es with or without C3 
fragments in absence or in presence of antibody. In experiments 2 and 3, modulation 
markedly  reduced  ADCC.  The  presence  of C3  fragments  on  the  target,  however, 
markedly enhanced the cells' cytotoxicity, which was dependent on antibody dose. In 
experiment 3, lysis of C3-fragment-bearing cells could be detected even in the absence 
of antibody. 
Demonstration  of  C3bi  Receptors  on  Lymphocytes  in  Addition  to  Receptors  for  C3b  and 
C3d.  The  interaction  of lymphocytes with  EbC3b,  EbC3bi,  or  EbC3d  was  studied 
using a  rosetting assay. Table III shows the results obtained with lymphocytes from 
six  different  donors.  Three  different  preparations  of C3  were  used.  As control,  the 
lymphoblastoid cell lines Raji and  Daudi were included.  Peripheral blood lympho- 
cytes formed rosettes with all three types of indicator cells. There was no difference in 
the size of the rosettes, regardless of the type of fragments used. However, the percent 
of  rosettes  formed  with  different  indicator  cells  varied  significantly.  The  percent 
rosettes  formed  with  EbC3b  was  almost  twice  that  with  EbC3bi  and  5-  to  10-fold 
higher than with EbC3d.  Both Raji and Daudi cells formed very strong rosettes with 
TABLE  II 
Effect of Target Cell-bound C3 Fragments on Cytotoxicity of FcyR-modulated Lymphocytes 
~lCr release at different concentrations of anti-Eb§ 
Sponta-  Modulated lymphocytes 
Exp.*  Target cells  neous  Control lymphocytes (~g IgG/ml) 
release~  (#g IgG/ml) 
0  0.13  0.4  1.3  4.0  13  0  0.13  0.4  1.3  4.0  13 
Es  5  9  23  40  51  5  7  25  30 
E,C3b  10  t2  47  62  71  16  20  53  60 
Es  20  12  28  11  17 
E~C3b  23  11  39  14  43 
E~C3bi  18  16  56  15  53 
E~  13  12  44  14  17 
EsC3b  20  26  58  33  64 
EsC3bi  22  30  77  35  7l 
E.C3d  24  27  72  24  57 
* Experiment  1:~50,000 C3b-Es; lymphocytes modulated with Eb-anti-Eb for 20 h. Experiment 2:~20,000 
C3b/E.; lymphocytes modulated with Ec-anti-Ec for 40 h. Experiment  3:~90,000 C3b/E~; lymphocytes 
modulated with Ec-anti-Ec for 20 h. 
:~ Percent 51Cr-release  from E8 in lymphocyte-free controls. 
§ Percent total S~Cr-release  (uncorrected) after 18 h, lymphocyte:target  cell ratios of 4:1. PERLMANN,  PERLMANN,  SCHREIBER,  AND  MfJLLER-EBERHARD 
TABLE III 
Binding of C3-Fragment-bearing Eb by Lymphoid Cells 
1597 
Percent rosettes* 
Exp. 
EbC3h  EbC3bi  EbC3d 
Lympho-  Raji  Daudi  Lympho-  Raji  Daudi  Lympho-  Raji  Daudi 
cytes:[:  cytes  cytes 
1  13.0  64  <1  8.8  >95  >95  1.4  >95  >95 
2  10.1  20  0  5.2  >95  >95  5.2  >95  -80 
3  10.5  <5  0  7.1  >95  >95  1.7  >95  ~60 
4  10.4  ~90  NDII  3.0  >95  ND  0.5  >95  ND 
5  11.3  42  0  4.3  >95  ND  1.0  >95  ~60 
6  10.2  ND  ND  5.5  ND  ND  1.0  ND  ND 
10.9 +  1.1§  -44  0  5.7 +  2.1  ~95  ~95  1.8 4- 1.7  ~95  ~70 
* C3-fragment-bearing  Eb made up freshly for each experiment.  No rosettes were formed in 
included in every experiment. 
:~ From six different donors. 
§ Means 4- SD. 
[[ Not done. 
Eb controls 
Fro.  2.  Photomicrographs  of Raji cells forming rosettes with EbC3b (a), EbC3bi (To), and EbC3d 
(c). 
EbC3bi and EbC3d. In both instances, a  large number of indicator cells was bound to 
lymphoblastoid cells. Raji cells, but not Daudi cells, also bound EbC3b. However, the 
frequency of these rosettes was low and the rosettes were weak, and contained fewer 
indicator cells. (Fig. 2) 
Heterogeneity of Lymphocytes with Respect to Type of Complement Receptor.  C3-fragment- 
binding lymphocytes were depleted from the effector cell preparations by two different 
methods:  (a)  adsorption  of lymphocytes  to  monolayers  of C3-fragment-bearing  Eb, 
and  (b)  formation  of rosettes  with  C3-fragment-bearing  Eb,  followed  by separation 
from nonrosetting lymphocytes by centrifugation. 
Table IV shows the distribution of C3 receptors among cells that did not adsorb to 
EbC3d  monolayers.  The  cells  recovered  in  the  supernate  were  then  layered  onto 
EbC3bi monolayers. Each depletion step removed ~20% of the lymphocytes originally 
added.  There  was  no  selective  loss  of EbC3b  rosetting  cells.  The  yield of EbC3bi- 
binding cells after C3d depletion was slightly lower than the total yield. C3bi depletion 
resulted in  a  very significant, but  not  complete, reduction of EbC3bi  rosetting cells. 
Similarly, C3d depletion reduced the number of EbC3d rosetting cells. The extent of 1598  ENHANCEMENT  OF ANTIBODY-MEDIATED CELLULAR CYTOTOXICITY 
TABLE IV 
Fractionation of Lymphocytes by Sequential Adsorptions to C3-fragment-bearing Eb Monolayers 
Lymphocytes 
Percent 
recovery 
after de- 
pletion* 
Percent rosettes 
EbC3b  EbC3bi  EbC3d 
Fre-  Rccov-  Fre-  Recov-  Fre-  Recov-  quency  :~  cry§  quency  cry  quency  cry 
Control  100  10.5  100  7.6  100  1.9  100 
EbC3d depleted  83  12.3  ~99  6.3  74  <0.5  <20 
EbC3bi depleted after EbC3d de-  63  11.0  67  1.6  15  <0.5  <20 
pletion 
* Recovery of lymphoeytes in supernates after monolayer adsorption, given as percent of original input 
(= I00). 
:~  Frcqucncies of  rosettc-forming  lymphocytes in  supernates after  monolaycr adsorption assayed by addition 
of  fresh  Eb-intermcdiates (no rosettes  present in supcrnatcs bcforc assay). 
§ Recoveries of rosette-forming lymphocytcs in supcrnatcs after  adsorption, given as percent of original 
input (ffi  100). 
TABLE V 
Fractionation of Lymphocytes by Rosetting with C3-Fragment-bearing Eh 
Percent rosettes 
Pcrccnt 
Lymphoeytes  recovery  EbC3b  EbC3bi  EbC3d 
after de- 
pletion*  Fre-  Recov-  Fre-  Reeov-  Fre-  Recovery  quency:~  cry§  quency  cry  quency 
Control  100  10.5  100  5.5  100  1.0 
EbC3d depleted  75  10.0  71  3.5  48  <~0.5  NCII 
EbC3b + EbC3d depleted  66  <1  <6  2.0  24  ,~0.5  NC 
* Recovery of lymphocytes in supernates after rosettes depletion, given as percent of original input (ffi 100). 
:~ Frequencies  of rosette-forming  lymphocytes in supernates after depletion, assayed by addition of fresh Eb- 
intermediates (no rosettes present in supernates before assay). 
§ Recoveries  of rosette forming lymphocytes  in supernates after depletion, given as percent of original input 
(= 100). 
II Not calculated. 
this depletion is not certain because of the low frequency of EbC3d rosetting cells in 
this experiment, 
Table V  summarizes the results of an experiment in which depletion was performed 
by rosetting with either EbC3d or with a  mixture consisting of equal parts of EbC3b 
and EuC3d. It will again be noted that C3d depletion did not selectively diminish the 
number of C3b rosetting cells. Only very few remaining C3d rosettes were seen after 
this step.  The  frequency of C3bi rosetting cells was  also decreased.  Depletion with 
mixtures  of  EbC3b  and  EbC3d  removed  >90%  of  the  EbC3b  rosetting  cells  and 
apparently all  EuC3d  rosetting cells,  whereas  ~25%  of the  EbC3bi  rosetting cells 
remained in the supernate. 
Inhibition of ADCC by C3-Fragment-bearing Bystander Cells.  To explore whether inter- 
action of lymphocytes with erythrocyte-bound C3 fragments results in the release of 
a  soluble ADCC-enhancing factor, unlabeled Eb, bearing either C3b, C3bi or C3d, 
were  mixed  with  an  equal  number of  5aCr-labeled  erythrocytes  not  bearing  C3 PERLMANN, PERLMANN, SCHREIBER, AND MOLLER-EBERHARD  1599 
fragments.  Different  dilutions  of antibody to  Eb  were added  to the  lymphocyte-Eb 
mixtures.  Fig. 3 indicates that no soluble factor that would enhance lysis  of C3-free 
cells  was  released  under  these  conditions.  On  the  contrary,  the  presence  of C3- 
fragment-bearing Eb in the incubation mixtures inhibited lysis of the C3-free targets. 
Inhibition by C3-fragment-bearing Eb was also observed when Ec was used as target 
cells  in the presence of anti-Ec antibodies which did not cross-react with Eb. 
Discussion 
The data presented in this paper show that lymphocytes that participate in ADCC 
may have receptors reacting with target cell-bound C3bi in addition to those reacting 
with  C3b and C3d.  All three cell-bound C3 fragments enhanced ADCC, but  C3bi 
and C3d enhanced the reaction much more strongly than C3b. The data also show 
that  in  absence  of specific  antibody,  cytotoxicity was  not  induced  in  spite  of the 
presence of up to  100,000 C3-fragments/target cell,  which is in agreement with our 
earlier results  (2). 
Approximately 40%  of the lymphocytic effector cells  of ADCC have receptors for 
activated C3 as assessed by rosetting of individual effector cells  in the ADCC plaque 
assay (23, 24). At least two distinct receptors reacting with C3b or C3d have previously 
been  found on human  peripheral  blood lymphocytes and other cells  (25,  26).  The 
C3b  receptor  (CR1  or  immune  adherence  receptor)  is  present  on  erythrocytes, 
lymphocytes, polymorphonuclear leukocytes (PMN), and monocytes and reacts with 
the intact C3b-molecule. The C3d receptor (CR2) is present on lymphocytes, but not 
on  PMN  or  monocytes and  reacts  with  the  C3d-fragment  (26-28).  Recently,  the 
occurrence of an additional receptor on human PMN and monocytes with specificity 
for C3bi (CR3) was proposed (29). The C3bi receptor has also been found on human 
glomeruli  (24)  and  on  rat  peritoneal  mast  cells  (30).  In  this  study,  using  human 
peripheral blood lymphocytes, ~ 11% of the cells bound EC3b, 6% bound EC3bi, and 
2% bound EC3d. Raji cells bound EC3b weakly and with different frequencies when 
different batches of these cells were tested.  In contrast, most Raji cells  formed large 
rosettes  with  either  C3bi- or C3d-indicator cells.  The latter was also the case with 
Daudi  cells  which,  however, did  not  bind  EbC3b.  This  is  in  accord with  previous 
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Fro.  3.  Inhibition of ADCC by C3-fragment-bearing  bystander cells. The target cell samples were 
mixtures of equal numbers of ~tCr-labeled Eb and unlabeled Eb (O), EbC3b (A), EhC3bi (O), or 
EhC3d (A). Bystander  cells carried 67,500 C3 fragments/cell. Experiment was performed as outlined 
in Materials and Methods and Fig. L 1600  ENHANCEMENT OF ANTIBODY-MEDIATED CELLULAR CYTOTOXICITY 
findings  indicating  that  Daudi  cells  lack  the  C3b  receptor,  but  possess  the  C3d 
receptor (31, 32). 
Evidence was  obtained  indicating  that  the  distribution  of C3  receptors  among 
human peripheral blood lymphocytes is nonhomogeneous. The results of the depletion 
experiments indicated that lymphocytes bearing C3b receptors are distinct from those 
bearing C3bi and/or C3d receptors. No definite conclusion could be reached regarding 
the differential expression of C3bi and C3d receptors on these lymphocytes. However, 
in unpublished studies, further insights in these questions have recently been gained 
by using the ADCC plaque assay (23, 24). C3bi receptor bearing plaque-forming cells 
(PFC) were more than twice as frequent than C3b receptor PFC. C3d receptor PFC 
were even fewer than C3b receptor PFC. Further, plaques were formed on monolayers 
of Eb that bore antibody and either C3b, C3bi, or C3d. Subsequently the PFC were 
incubated  with  Eb that  bore one of the three fragments but  not  antibody.  Under 
those conditions, the majority of the PFC rosetted with those cells that carried the 
same C3 fragments as the target cells. Most of the PFC with receptors for C3d also 
had  receptors  for C3bi.  The  PFC  that  carried  both  the  C3bi  and  C3d  receptors 
appeared to be T cells, as judged by surface-marker analysis, whereas the C3b receptor 
PFC were null cells. A  detailed account of these results will be published elsewhere 
(B.  W~ihlin,  H.  Perlmann,  P.  Perlmann,  R.  Schreiber,  and  H.  Miiller-Eberhard, 
manuscript in preparation). 
It has been reported that EAC-rosetting of  C3-receptor bearing lymphocytes induces 
the  release of lymphotoxin-like factors, which  enhance  the  natural  cytotoxicity of 
lymphocytes to nucleated target cells (33).  The present results do not support a  role 
for soluble factors in this system. The exposure of lymphocytes to C3 fragments before 
the  cytotoxicity assay  did  not  increase  their  natural  cytotoxicity to  Eb,  nor  their 
ADCC potential. Admixture of C3-fragment bearing target cells to ~lCr-labeled, C3- 
fragment-free target cells did not enhance ADCC of the labeled cells. Enhancement 
should have occurred if a soluble enhancing factor had been generated in the presence 
of C3 fragments. 
The target  cell-mixing experiments gave additional  information. To achieve en- 
hancement  of ADCC,  antibody and  C3  fragments had  to reside on the same cell. 
When cells were introduced into the reaction mixture which carried C3  fragments 
but no antibody, lysis of antibody-coated cells was inhibited. The inhibitory capacity 
of the fragments ranked in the same order as their enhancing capacity: C3bi >  C3d 
>> C3b. Presumably, this inhibition of ADCC is a result of competitive binding of the 
C3-fragment-bearing cells to the effector cells. 
Taken  together,  the  results  described  in  this  paper  show  that  cell-bound  C3 
fragments ha+e an important role in regulating ADCC. Because this reaction requires 
target cell-effector cell contact (1) C3 fragments on the surface of the target cells may 
enhance cytotoxicity through interaction with C3 receptors on the effector cells. That 
C3bi and C3d are more efficient in enhancing ADCC than C3b may be biologically 
significant.  Although  complement  activation  via  the  classical  or  the  alternative 
pathway  leads  to deposition of C3b  on  the target  cell  surface, the  structural  and 
functional integrity of C3b is under rigid temporal constraints. Owing to the cooper- 
ative action of~lH and the C3b inactivator, C3b is converted to C3bi, which in turn 
is degraded to C3d. Because C3b conversion is a rapid process, the predominant forms 
of cell-bound C3 are C3bi and C3d. Neither of these fragments is capable of sustaining PERLMANN, PERLMANN, SCHREIBER, AND MULLER-EBERHARD  1601 
the cytolytic reaction which would  result  in  the formation of the membrane attack 
complex  and  cell  death.  However,  because  C3bi  and  C3d  are  more  efficient  in 
enhancing ADCC  than  C3b,  these  fragments may facilitate cellular surveillance in 
the presence of minute amounts of antibody. 
Summary 
The  occurrence  and  distribution  of distinct  receptors  for three  C3  fragments on 
purified human blood lymphocytes were studied by rosette formation. Indicator cells 
were bovine, chicken, or sheep erythrocytes (E)  bearing up to  100,000  molecules of 
human  C3b  (EC3b)  without  antibody.  EC3b  was  converted  to  C3bi-bearing-E 
(EC3bi)  with  purified C3b  inactivator  (factor I) and fllH  (factor H), and  to C3d- 
bearing  E  (EC3d)  by  treatment  of EC3bi  with  trypsin.  Using  bovine  E  (Eb)  as 
indicators, -11% of the lymphocytes bound EbC3b, 6% bound EbC3bi and 2% bound 
EbC3d. Fractionation of the lymphocytes by adsorption to monolayers of C3-fragment- 
bearing Eb or by rosetting indicated that most of the cells with receptors for C3b were 
distinct  from those having receptors for C3bi  and/or C3d.  Cells from two lympho- 
blastoid cell lines (Raji and Daudi) formed strong rosettes with either EC3bi or EC3d. 
A fraction of the Raji cells, but not of Daudi cells formed rosettes with EC3b, which 
were weak. SlCr-labeled E  was used as a  target in antibody-dependent, lymphocyte- 
mediated cytotoxicity (ADCC).  In the absence of antibody, C3-fragment-bearing E 
was  not  lysed  by the  lymphocytes. However, at  suboptimal  concentrations  of IgG 
anti-E  antibody,  ADCC  of  C3-fragment-bearing  E  was  strongly  enhanced.  The 
enhancing capacity of the fragments occurred in the order of C3bi >  C3d >> C3b. In 
addition,  C3-fragment-bearing cells inhibited  the  lysis of antibody-coated  cells not 
bearing  C3  fragments.  Inhibition  ranked  in  the  same order  as  enhancement.  It  is 
concluded that target cell bound C3 fragments enhance ADCC by improving contact 
between target cells and those effeetor cells which have C3 receptors. Cell-bound C3 
fragments  inhibit  ADCC  of C3-free  targets  by  impeding  their  contact  with  such 
effector cells. It is proposed that certain lymphocytes are capable of interacting with 
C3bi in addition  to C3b and C3d and that C3bi and C3d have a  greater regulatory 
effect on their cytolytic function than C3b. 
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